XOMA (XOMA Royalty) Research & Development: $0.47 Mil (TTM As of Mar. 2026)


XOMA XOMA Royalty Corp XOMA
45 GF Score
Price $42.15
GF Value $18.85
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is XOMA Royalty Research & Development?

XOMA Royalty XOMA -0.12% 45 Research & Development is $0.47 Mil as of Mar. 2026. GuruFocus rates XOMA with a GF Score™ of 45/100 and a GF Value™ of $18.85 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. XOMA Royalty's Research & Development for the three months ended in Mar. 2026 was $0.05 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.47 Mil.

XOMA Royalty  (NAS:XOMA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

XOMA Royalty Research & Development Related Terms

XOMA Royalty Research & Development Historical Data

* Premium members only.

The historical data trend for XOMA Royalty's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA Royalty Research & Development Chart

XOMA Royalty Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.15 0.14 2.88 1.71

XOMA Royalty Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 0.07 0.07 0.28 0.05
XOMA
45GF Score
XOMA Royalty Corp XOMA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XOMA Royalty Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.47 Mil mean?
XOMA Royalty (XOMA) has a Research & Development of $0.47 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on XOMA Royalty and its competitors.
Is XOMA Royalty's Research & Development too high?
XOMA Royalty's current Research & Development is $0.47 Mil. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's Research & Development compare to EDIT and FDMT?
XOMA Royalty's Research & Development of $0.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on XOMA Royalty and its competitors. XOMA Royalty's current Research & Development is $0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.85, compared to a current price of $42.15 — trading 123.6% above its estimated fair value. The current Research & Development is $0.47 Mil. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current Research & Development is $0.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XOMA Royalty (XOMA) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $42.15 is trading 123.6% above its estimated GF Value™ of $18.85. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for XOMA:

  • Research & Development: $0.47 Mil
  • GF Value™: $18.85 vs. price of $42.15 (123.6% above fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score

Get the complete analysis for XOMA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.15
Price
$18.85
GF Value